分类： ACN Newswire

LONDON, Dec 2, 2024 - (ACN Newswire via SeaPRwire.com) - Spritzer has once again demonstrated its dominance in the bottled water industry by being named "Brand of the Year" in the national beverage division’s Water Category at the prestigious 2024–2025 World Branding Awards. The recognition marks Spritzer’s 10th consecutive win at the global awards, a testament to the brand’s enduring excellence in quality, branding, and consumer trust which further solidifies its position as Malaysia’s leading mineral water brand.Spritzer’s Head of Public Relations, Winnie Chin, accepting the Brand of the Year award under the national beverage division’s Water Category during the recent World Branding Awards at the Tower of LondonThe accolade was awarded by the World Branding Forum (WBF), a global non-profit organization devoted to advancing branding standards worldwide, at the annual World Branding Awards event which recognizes exceptional global and national brands across various categories. Winners in each category were evaluated through a rigorous process involving brand valuation, market research, and online public voting, showcasing a holistic assessment of brand strength and consumer trust. Most importantly, as the award evaluation relies heavily on consumer voting (70%), Spritzer’s continued wins over the years demonstrates the brand’s ability to consistently resonate with audiences and exceed customer expectations.Accepting the award on behalf of Spritzer during the awards ceremony held at the iconic Tower of London was Winnie Chin, Spritzer’s Head of Public Relations, who acknowledged the profound significance of this milestone: “We are honoured to receive this award for the 10th year running. Our achievements would not be possible without the unwavering support of our consumers, whose steadfast loyalty has made the Spritzer brand a household name. We also extend our gratitude to our partners for their collaboration and support and especially to our dedicated team for their hard work and creativity that have made this journey possible. We are deeply humbled and motivated to continue elevating our brand to greater heights, to build on Spritzer’s brand strength and commitment to excellence in all aspects of our company.”The award is a milestone that recognises Spritzer as a benchmark for consistency and adaptability to maintain brand trust and address emerging consumer needs in the ever-evolving market landscape. The company’s consistency, adaptability, and innovation have not only propelled it to the forefront of Malaysia’s bottled water industry but have also established it as a benchmark for quality, sustainability and innovation on a global stage. Spritzer’s decade-long winning streak at the awards exemplifies the brand’s commitment to producing high-quality natural bottled water and its reputation as a consumer-preferred brand.Building on this monumental achievement, Spritzer reaffirms its commitment to quality assurance as it continues to deliver bottled water with natural benefits and premium standards. The brand emphasises its dedication to sustainability goals and innovation as it continues to focus on advancing efforts to become a circular brand by 2030, aligned with global environmental initiatives, while leveraging cutting-edge technologies to introduce consumer-focused solutions to meet emerging needs.For more details about Spritzer, please visit our website at https://www.spritzer.com.my/.About Spritzer:Established in 1989, Spritzer Group has been a pioneer in providing Malaysians with natural mineral water sourced from a 440-acre green rainforest. Committed to innovation, Spritzer Group leads the Malaysian bottled water industry through manufacturing, distribution, marketing, and sales of its diverse product line. From renowned natural mineral water to refreshing non-carbonated fruit-flavoured drinks, each product is carefully crafted to meet consumer needs.Comprising eight business subsidiaries, Spritzer Group specializes in the production and distribution of silica-rich natural mineral water, sparkling natural mineral water, distilled drinking water, carbonated fruit-flavoured drinks, and non-carbonated fruit-flavoured drinks.With over 30 years of experience, Spritzer Group is Malaysia's largest and only listed bottled water producer. For more information, please visit www.spritzer.com.my. Copyright 2024 ACN Newswire via SeaPRwire.com.

SHANGHAI, Dec 2, 2024 - (ACN Newswire via SeaPRwire.com) - Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing and commercialization of innovative therapeutics, today announced that Department of Health of the Government of the Hong Kong Special Administrative Region, China, has accepted Everest’s New Drug Application (NDA) for VELSIPITY(R) (etrasimod) for the treatment of adult patients with moderately to severely active ulcerative colitis.  VELSIPITY(R) is an effective and convenient, once-daily, oral treatment for patients with moderately-to-severely active UC that has already been approved in the U.S. and E.U., and other countries, by Everest’s licensing partner, Pfizer. In Everest territories, the Pharmaceutical Administration Bureau of the Macau Special Administrative Region, China has approved the NDA for VELSIPITY(R) in April of this year and was implemented in the Guangdong-Hong Kong-Macau Greater Bay Area this October through the "Hong Kong and Macau Medicine and Equipment Connect" policy."Autoimmune disease is a core focus and a significant growth driver for our company. The number of UC patients in China is projected to double from 2019 to 2030 to approximately one million, highlighting the urgent need for novel treatments." said Rogers Yongqing Luo, Chief Executive Officer of Everest Medicines. “Previously, VELSIPITY(R) has already been approved in Macau, China, and was implemented in the Greater Bay Area through the connect policy. The company also plans to submit the NDA for approval by China’s National Medical Products Administration (NMPA) this year, with the aim of benefiting more Chinese patients as soon as possible."" This is an important advancement for etrasimod, bringing hope to patients in Hong Kong, China. This new-generation S1P receptor modulator is an oral, once-daily treatment that can provide patients with a chance for corticosteroid-free remission, mucosal healing, and rapid symptom relief, " said Prof. Wu Kaichun with the First Affiliated Hospital of AFMU who is the principal investigator for etrasimod’s Asia clinical trial. “We hope China and other Asian countries can obtain approvals as soon as possible to benefit more patients."The acceptance of the NDA was based on results from the ELEVATE UC Phase 3 registrational program (ELEVATE UC 52 and ELEVATE UC 12) that evaluated the safety and efficacy of etrasimod 2 mg once-daily on clinical remission in UC patients with moderately to severely active UC who had previously failed or were intolerant to at least one conventional, biologic, or Janus kinase (JAK) inhibitor therapy. Nearly two-thirds of patients in ELEVATE UC 52 and ELEVATE UC 12 were naïve to biologic or JAK inhibitor therapy, and these studies were also the only studies for advanced therapies for ulcerative colitis to include patients with isolated proctitis. Both studies achieved all primary and key secondary efficacy endpoints, with a favorable safety profile consistent with previous studies of etrasimod.Everest conducted a multicenter, randomized, double-blind and placebo-controlled Phase 3 trial of etrasimod in Asian countries, including mainland China, China Taiwan and South Korea. This is the largest Phase 3 trial of moderately-to-severely active ulcerative colitis in Asia completed to date, with 340 eligible subjects randomized to treatment with etrasimod or placebo. The previously announced results of the induction period indicate that the clinical remission rate for patients treated with etrasimod 2mg was 25.0%, compared to 5.4% for those treated with placebo (difference 20.4%, p<0.0001). Compared to the placebo group, patients treated with etrasimod demonstrated significant clinical and statistically significant improvements in all key secondary endpoints. Subsequently, the topline results from maintenance period released in July of this year confirmed that after 40 weeks of treatment, etrasimod demonstrated significant clinical and statistical improvements over placebo in the primary and all key secondary endpoints (p<0.0001), and other secondary endpoints (including mucosal healing and endoscopic normalization, both p<0.0001). The safety profile of etrasimod was consistent with previous studies, with no new safety signals observed. The results of the maintenance period will be released at an international academic conference.About VELSIPITY(R) (etrasimod)VELSIPITY(R) is a once-daily, oral, sphingosine 1-phosphate (S1P) receptor modulator that selectively binds with S1P receptor subtypes 1, 4, and 5. Regulatory approvals have been granted in US, EU, Canada, Australia, Singapore, UK, Switzerland, Israel and Macau, China for VELSIPITY(R) in ulcerative colitis.About Everest MedicinesEverest Medicines is a biopharmaceutical company focused on discovering, developing, manufacturing and commercializing transformative pharmaceutical products and vaccines that address critical unmet medical needs for patients in Asian markets. The management team of Everest Medicines has deep expertise and an extensive track record from both leading global pharmaceutical companies and local Chinese pharmaceutical companies in high-quality discovery, clinical development, regulatory affairs, CMC, business development and operations. Everest Medicines has built a portfolio of potentially global first-in-class or best-in-class molecules in the company’s core therapeutic areas of renal diseases, infectious diseases and autoimmune disorders. For more information, please visit its website at www.everestmedicines.com.Forward-Looking Statements:This news release may make statements that constitute forward-looking statements, including descriptions regarding the intent, belief or current expectations of the Company or its officers with respect to the business operations and financial condition of the Company, which can be identified by terminology such as “will,” “expects,” “anticipates,” “future,” “intends,” “plans,” “believes,” “estimates,” “confident” and similar statements. Such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, or other factors, some of which are beyond the control of the Company and are unforeseeable. Therefore, the actual results may differ from those in the forward-looking statements as a result of various factors and assumptions, such as future changes and developments in our business, competitive environment, political, economic, legal and social conditions. The Company or any of its affiliates, directors, officers, advisors or representatives has no obligation and does not undertake to revise forward-looking statements to reflect new information, future events or circumstances after the date of this news release, except as required by law. Copyright 2024 ACN Newswire via SeaPRwire.com.

上海, 2024年12月2日 - (亚太商讯 via SeaPRwire.com) - 云顶新耀（HKEX 1952.HK）是一家专注于创新药研发、临床开发、制造和商业化的生物制药公司，今日宣布中国香港卫生署已正式受理伊曲莫德（VELSIPITY(R)）用于治疗中重度活动性溃疡性结肠炎成人患者的新药上市许可申请（NDA）。伊曲莫德是一款每日一次口服的一线先进疗法，不仅使用方便、疗效佳，而且具有良好的安全性特征。伊曲莫德已于去年10月和今年2月先后在美国和欧盟获得新药上市批准，同时，伊曲莫德也于今年4月获得中国澳门特别行政区药物监督管理局批准上市，并于今年10月通过"港澳药械通"政策在粤港澳大湾区落地。云顶新耀首席执行官罗永庆表示："我们非常高兴看到伊曲莫德的新药上市许可申请在中国香港获得正式受理。自身免疫性疾病是我们的重点关注领域和重要价值的潜在增长动力。到2030年，中国的溃疡性结肠炎患者人数预计将达到约100万人，超过2019年患者人数的一倍以上，存在迫切且巨大的未被满足的临床需求。伊曲莫德已在中国澳门获批，并通过"港澳药械通"政策率先在粤港澳大湾区落地。今年我们预计也将在中国大陆地区递交伊曲莫德的新药上市许可申请。期待伊曲莫德在更多地区获批，进一步扩大可及性，造福广大患者。"伊曲莫德亚太临床试验牵头研究者、世界胃肠病学会执行理事、亚太消化学会副主席、中国人民解放军空军军医大学附属西京医院吴开春教授表示："祝贺伊曲莫德取得的这一新进展，为中国香港的患者带来了希望。伊曲莫德具有良好的获益-风险特征，这种新一代S1P受体调节剂通过每日一次口服的治疗方案，可快速起效，并达到无激素缓解、黏膜愈合，可为中重度活动性溃疡性结肠炎成人患者提供先进的治疗选择。我们期待伊曲莫德在大中华区及其他亚洲国家早日获批，为患者带来福音。"伊曲莫德的申请是基于ELEVATE UC III期注册研究（ELEVATE UC 52和ELEVATE UC 12）的结果，该研究旨在评价既往对至少一种常规治疗、生物制剂或Janus激酶（JAK）抑制剂治疗失败或不耐受的中重度活动性溃疡性结肠炎患者，每日一次服用2mg 伊曲莫德的安全性和疗效。在ELEVATE UC 52和ELEVATE UC 12中，纳入了一半以上严重活动性溃疡性结肠炎患者（mMS≥7），并有近三分之一患者曾接受过生物制剂或JAK抑制剂治疗。伊曲莫德的UC研究也是迄今唯一纳入了孤立性直肠炎患者的UC研究。这两项随机、双盲、安慰剂对照研究均达到了所有主要和关键次要终点，安全性特征与既往研究一致。在ELEVATE UC 52研究中，第12周时，接受伊曲莫德治疗的患者临床缓解率为27.0%（安慰剂组7.0%, 差异20.0%，P<0.001）；第52周时，接受伊曲莫德治疗的患者临床缓解率为32.0%（安慰剂组7.0%，差异26.0%，P<0.001）。在ELEVATE UC 12研究中，接受伊曲莫德治疗的患者12周临床缓解率为26.0%（安慰剂组15.0%，差异11.0%，P<0.05）。在这两项研究中，伊曲莫德治疗组所有关键性次要终点均达到统计学意义的显著改善，包括第12周和52周的临床应答、内镜改善和组织学内镜下黏膜改善终点以及第52周的无激素缓解和持续临床缓解。伊曲莫德的安全性与之前的研究一致，最常见的不良反应是贫血和头痛。云顶新耀在亚洲地区（包括中国大陆、中国台湾和韩国）开展的伊曲莫德多中心、随机、双盲、安慰剂对照III期研究，是迄今为止完成的最大规模的亚洲中重度溃疡性结肠炎的III期注册临床研究，总计 340名中重度溃疡性结肠炎患者随机接受伊曲莫德或安慰剂治疗。此前公布的诱导期结果显示，伊曲莫德2mg治疗的患者的临床缓解率为25.0%，安慰剂治疗的患者为5.4%（差值20.4%，p<0.0001）。与安慰剂组相比，伊曲莫德治疗的患者所有关键次要终点均有显著的临床意义和统计学意义的改善。随后，今年7月份公布的维持期顶线结果证实，在经过40周的维持期治疗后，伊曲 莫德组与安慰剂组相比，主要终点和所有关键次要终点均具有显著的临床意义和统计学意义（p<0.0001）的改善，其他包括黏膜愈合、内镜恢复正常等的次要终点也均达到具有显著临床意义和统计学意义（p<0.0001）的改善。维持期治疗显示了伊曲莫德良好的安全性，安全性数据与已知特征一致，没有观察到新的安全性信号。维持期的研究结果将在近期的国际学术会议发布。关于伊曲莫德（VELSIPITY(R), etrasimod）伊曲莫德（VELSIPITY(R)，etrasimod）是一种每日一次口服的高选择性鞘氨醇-1-磷酸（S1P）受体调节剂，采用优化的药理学设计，与S1P受体1、4和5结合。伊曲莫德目前已在美国、欧盟、加拿大、澳大利亚、英国、瑞士、以色列以及中国澳门和新加坡获得新药上市批准。关于云顶新耀云顶新耀是一家专注于创新药和疫苗研发、临床开发、制造和商业化的生物制药公司，致力于满足亚洲市场尚未满足的医疗需求。云顶新耀的管理团队在中国及全球领先制药企业从事过高质量研发、临床开发、药政事务、化学制造与控制（CMC）、业务发展和商业化运营，拥有深厚的专长和丰富的经验。云顶新耀已打造多款疾病首创或者同类最佳的药物组合，公司的治疗领域包括肾科疾病、感染性和传染性疾病、自身免疫性疾病。有关更多信息，请访问公司网站：www.everestmedicines.com。前瞻性声明本新闻稿所发布的信息中可能会包含某些前瞻性表述，乃基于本公司或管理层在做出表述时对公司业务运营情况及财务状况的现有看法、相信、和现有预期，可能会使用"将"、"预期"、"预测"、"期望"、"打算"、"计划"、"相信"、"预估"、"确信"及其他类似词语进行表述。这些前瞻性表述并非对未来业绩的保证，会受到风险、不确定性及其他因素的影响，有些乃超出本公司的控制范围，难以预计。因此，受我们的业务、竞争环境、政治、经济、法律和社会情况的未来变化及发展等各种因素及假设的影响，实际结果可能会与前瞻性表述所含资料有较大差别。本公司及各附属公司、各位董事、管理人员、顾问及代理未曾且概不承担更新该稿件所载前瞻性表述以反映在本新闻稿发布日后最新信息、未来项目或情形的任何义务，除非法律要求。 Copyright 2024 亚太商讯 via SeaPRwire.com.

SHANGHAI, Nov 30, 2024 - (ACN Newswire via SeaPRwire.com) - Hua Medicine (the “Company”, HKEx stock code: 2552) announced today that the Company has successfully completed a Phase I clinical trial on its 2nd generation GKA candidate in U.S. at the 9th China BioMed Innovation and Investment Conference (CBIIC).The Phase Ia clinical trial of the second-generation GKA (HM-002-1005) was conducted in the United States in 40 subjects with Type 2 diabetes (T2D). This trial was randomized, double-blind, placebo-controlled, single-dose, focusing on safety, tolerability, and pharmacokinetics. The second-generation GKA is a novel molecular entity with optimized physicochemical properties, holding new patents, and serving as the prodrug of dorzagliatin (HMS5552). This study designed for once-daily oral administration. Its aim is to extend the drug's action duration in the body through sustained-release technology, enhance patient compliance, and prolong the stimulation of GLP-1 secretion in the intestines.The Single Ascending Dose (SAD) study demonstrates that HM-002-1005 tablets can be rapidly converted to HMS5552 in the human body, with minimal exposure level of prodrug in both blood and urine. The t1/2 (biological half-life) after a single dose of HM-002-1005 tablets was prolonged compared to dorzagliatin tablets. The Cmax of HMS5552 in plasma after a 184.5mg single dose is comparable to the plasma concentration of HMS5552 after a 75mg single dose of dorzagliatin tablet; likewise, the daily AUC of HMS5552 in plasma after a single dose of HM-002-1005 tablets is comparable to the exposure level of HMS5552 after a 75mg BID dose of dorzagliatin tablets. The research indicates that HM-002-1005 tablets are near-completely converted to HMS5552 in human, and its pharmacokinetic characteristics support for once-daily oral administration. The development of HM-002-1005 tablets not only contributes to enhancing patient medication adherence and effectively control blood glucose levels within 24 hours; meanwhile, it also offers the opportunity to explore the Maximum Tolerated Dose above 150mg daily to achieve better efficacy. The 75 mg BID dose regiment was developed under the concept of Minimum Therapeutic Effective Dose in Chinese T2D patients who suffered from an impairment of insulin secretion and significant reduction of early phase insulin. The different disease characters of T2D with obesity in western patient population would benefit dorzagliatin from its effects on GLP-1 secretion and improvement of insulin sensitivity.With the confirmation that the exposure level of HM-002-1005 tablets at 184.5mg is comparable to dorzagliatin tablets at 75mg (BID), we will further optimize the dosage form followed by a Multiple Ascending Dose (MAD) clinical development of the 2nd generation GKA in China and the United States.Dr. Li CHEN, founder and CEO of Hua Medicine, stated, “Hua Medicine has always been committed to treating Type 2 diabetes at its root cause by restoring patients’ ability to autonomously regulate blood glucose levels. Over the course of a decade, the Company has selected dosing and clinical research protocols that are safe and effective for the majority of Chinese diabetes patients, leading to the successful development of GKA and the clinical application of dorzagliatin. Building on this foundation, the Company will undergo a strategic upgrade by further exploring the therapeutic potential of GKA, enriching its product pipeline and seeking partners both domestically and internationally, in order to benefit a broader range of patients, expand into global markets, and effectively establish the brand identity of GKA medications while maximizing the commercial potential of our global first-in-class drugs.”About Hua MedicineHua Medicine (The “Company”) is an innovative drug development and commercialization company based in Shanghai, China, with companies in the United States and Hong Kong. Hua Medicine focuses on developing novel therapies for patients with unmet medical needs worldwide. Based on global resources, Hua Medicine teams up with global high-calibre people to develop breakthrough technologies and products, which contribute to innovation in diabetes care. Hua Medicine's cornerstone product HuaTangNing (Dorzagliatin tablets), targets the glucose sensor glucokinase, restores glucose sensitivity in T2D patients, and stabilizes imbalances in blood glucose levels in patients. HuaTangNing was approved by the National Medical Products Administration (NMPA) of China on September 30th, 2022. It can be used alone or in combination with metformin for adult T2D patients. For patients with chronic kidney disease (CKD), no dose adjustment is required. It is an oral hypoglycemic drug that can be used for patients with Type 2 diabetes with renal function impairment.For more informationHua MedicineWebsite: www.huamedicine.comInvestorsE-mail: ir@huamedicine.comMediaE-mail: pr@huamedicine.com Copyright 2024 ACN Newswire via SeaPRwire.com.

SHANGHAI, Nov 30, 2024 - (ACN Newswire via SeaPRwire.com) - Hua Medicine (the “Company”, HKEx stock code: 2552) announced today that the Company has successfully completed its SENSITIZE study on the mechanism by which dorzagliatin improves the β-cell glucose sensitivity at the 9th China BioMed Innovation and Investment Conference (CBIIC).The SENSITIZE study was initiated by Professor Juliana Chan, an international endocrinology specialist at The Chinese University of Hong Kong, as the lead researcher. It is the first clinical study in Asian populations to evaluate the impact of GKA on β-cell glucose sensitivity in the populations with varying degrees of impaired glucose tolerance using the technology of hyperglycemic clamp. The study aims to explore the impairment of glucokinase (GK) function and clinical characteristics in different types of glucose dysregulation, providing new scientific evidence on the pathophysiology of Asian Type 2 diabetes and the central role of GK in blood glucose regulation.The SENSITIZE 2 study results announced at CBIIC demonstrate that a single dose of dorzagliatin restores GK enzyme activity, significantly improving the second-phase insulin secretion and β-cell glucose sensitivity in individuals with impaired glucose tolerance (IGT) in hyperglycemic clamp study. In addition, the SENSITIZE 1 study previously reported at the 2022 ADA annual meeting showed that dorzagliatin directly restores the activity of GK mutants, leading to significant improvements in the second-phase insulin secretion and β-cell glucose sensitivity in patients with glucokinase monogenic diabetes (GCK-MODY or MODY-2), and significantly enhance basal insulin secretion in newly diagnosed type 2 diabetes patients.Hua Medicine will continue to investigate β-cell glucose sensitivity improvement and incretin effect in response of repeated dose of dorzagliatin in individuals with intermediate hyperglycemia (IH) and Type 2 diabetes, in order to establish personalized intervention and treatment management plans for prediabetic and Type 2 diabetes patients.About Hua MedicineHua Medicine (The “Company”) is an innovative drug development and commercialization company based in Shanghai, China, with companies in the United States and Hong Kong. Hua Medicine focuses on developing novel therapies for patients with unmet medical needs worldwide. Based on global resources, Hua Medicine teams up with global high-calibre people to develop breakthrough technologies and products, which contribute to innovation in diabetes care. Hua Medicine's cornerstone product HuaTangNing (Dorzagliatin tablets), targets the glucose sensor glucokinase, restores glucose sensitivity in T2D patients, and stabilizes imbalances in blood glucose levels in patients. HuaTangNing was approved by the National Medical Products Administration (NMPA) of China on September 30th, 2022. It can be used alone or in combination with metformin for adult T2D patients. For patients with chronic kidney disease (CKD), no dose adjustment is required. It is an oral hypoglycemic drug that can be used for patients with Type 2 diabetes with renal function impairment.For more informationHua MedicineWebsite: www.huamedicine.comInvestorsE-mail: ir@huamedicine.comMediaE-mail: pr@huamedicine.com Copyright 2024 ACN Newswire via SeaPRwire.com.

上海, 2024年11月30日 - (亚太商讯 via SeaPRwire.com) - 华领医药（"公司"，香港联交所股份代号：2552.HK）今天在第九届中国医药创新与投资大会（The China BioMed Innovation and Investment Conference，以下简称CBIIC）上宣布，已经成功完成在美国开展的第二代葡萄糖激酶激活剂（GKA）的Ia临床研究。第二代GKA（HM-002-1005）Ia临床试验是在美国40例2型糖尿病（T2D）受试者中进行的随机、双盲安慰剂对照、单剂量、安全性、耐受性、药代动力学研究。第二代GKA是一种具有优化的理化性质的新分子实体，拥有新专利，为多格列艾汀（HMS5552）前药。该项研究设计为每日一次口服给药，旨在通过缓释技术来延长药物在体内的作用时间、改善患者依从性以及延长刺激肠道内GLP-1分泌的效果。这一单次剂量递增（SAD）研究结果显示，HM-002-1005片在人体内可迅速转化为HMS5552，前药在血浆和尿液中的暴露量极低。HM-002-1005片单次给药后的t1/2（生物半衰期）相较于多格列艾汀片延长。184.5mg单次给药后，血浆中HMS5552的Cmax与多格列艾汀片75mg单次给药后的血浆HMS5552浓度相当；同时，血浆中HMS5552的单日AUC与多格列艾汀片75mg一天两次给药后HMS5552的暴露水平相当。该研究表明，HM-002-1005片在人体内几乎完全转化为HMS5552，且其药代动力学特征支持每日一次口服给药方式。HM-002-1005片的开发不仅有利于提高患者服药的依从性，实现24小时内有效控制血糖；同时，也为探索每日150mg以上的最大耐受剂量提供了机会，以获得更好的治疗效果。多格列艾汀75mg每日两次（BID）剂量是根据最低有效治疗剂量的治疗理念，针对中国2型糖尿病患者普遍存在的胰岛素分泌缺陷和早相胰岛素分泌显著降低而开发的剂型。西方2型糖尿病患者具有不同的疾病特点，往往合并肥胖症状，多格列艾汀能够促进GLP-1分泌、改善胰岛素敏感性，有望为该患者群体带来新的获益。该研究结果确认HM-002-1005片184.5mg的暴露水平与多格列艾汀片75mg BID相当，公司将进一步优化剂型，在中国和美国进行第二代GKA的多次递增剂量（MAD）临床开发。华领医药创始人、CEO陈力博士表示："华领医药始终致力于通过修复患者血糖自主调控能力，从源头上治疗2型糖尿病。公司历经十年，选择了针对大多数中国糖尿病患者安全有效的用药剂量方案和临床研究方案，实现了GKA的成功开发和多格列艾汀的临床应用。在此基础上，公司将进行战略升级，通过继续探索GKA的用药潜力、丰富产品管线，在国内外寻求合作伙伴，惠及更多患者人群、拓展全球市场，更好地实现GKA药物的品牌建设和全球首创新药的商业价值。"关于华领华领医药（"本公司"）是一家总部位于中国上海的创新药物研发和商业化公司，在美国、中国香港设立了公司。华领医药专注于未被满足的医疗需求，为全球患者开发全新疗法。华领医药汇聚全球医药行业高素质人才，融合全球创新技术，依托全球优势资源，研究开发突破性的技术和产品，引领全球糖尿病医疗创新。公司核心产品华堂宁(R)（多格列艾汀片）以葡萄糖传感器葡萄糖激酶为靶点，提升2型糖尿病患者的葡萄糖敏感性，改善患者血糖稳态失调。2022年9月30日，华堂宁(R)已获得中国国家药品监督管理局（NMPA）的上市批准，用于单独用药或者与二甲双胍联合用药，治疗成人2型糖尿病。对于肾功能不全患者，无需调整剂量，是一款可用于肾功能损伤的2型糖尿病患者的口服降糖药物。详情垂询华领医药网址：www.huamedicine.com投资者电邮：ir@huamedicine.com媒体电邮：pr@huamedicine.com Copyright 2024 亚太商讯 via SeaPRwire.com.

上海, 2024年11月30日 - (亚太商讯 via SeaPRwire.com) - 华领医药（"公司"，香港联交所股份代号：2552.HK）今天在第九届中国医药创新与投资大会（The China BioMed Innovation and Investment Conference，以下简称CBIIC）上宣布，公司已经成功完成与香港中文大学Juliana Chan教授团队合作开展SENSITIZE研究，该研究为多格列艾汀改善β细胞葡萄糖敏感性的作用机制研究。SENSITIZE研究是由国际内分泌专家、香港中文大学Juliana Chan教授作为研究者发起的，首个在亚洲人群中采用高葡萄糖钳夹技术评估GKA对不同血糖调节受损人群的β细胞葡萄糖敏感性影响的临床研究，以探索不同葡萄糖激酶（GK）功能损伤类型在血糖失调方面的临床特征和干预手段，为研究亚洲T2D病生理及GK在血糖调控中的核心作用提供了新的科学依据。此次报告的SENSITIZE 2研究结果显示，采用高葡萄糖钳夹技术，多格列艾汀单次给药修复GK酶活性，显著改善葡萄糖耐量异常（IGT）人群的二相胰岛素分泌和β细胞葡萄糖敏感性。而此前在2022年美国ADA年会上报告的SENSITIZE 1研究结果显示，多格列艾汀可直接修复临床纳入的GK突变型活性，可以显著改善葡萄糖激酶单基因遗传突变糖尿病 (GCK-MODY或MODY-2)患者的胰岛素第二时相分泌和β细胞葡萄糖敏感性，可以显著改善初发2型糖尿病患者的基础胰岛素分泌。华领医药还将继续研究多格列艾汀多次给药对中间高血糖（IH）和2型糖尿病患者β细胞葡萄糖敏感性的修复作用，以及对肠促胰岛素的作用，从而建立糖尿病前期和2型糖尿病患者的个性化干预和治疗管理方案。关于华领华领医药（"本公司"）是一家总部位于中国上海的创新药物研发和商业化公司，在美国、中国香港设立了公司。华领医药专注于未被满足的医疗需求，为全球患者开发全新疗法。华领医药汇聚全球医药行业高素质人才，融合全球创新技术，依托全球优势资源，研究开发突破性的技术和产品，引领全球糖尿病医疗创新。公司核心产品华堂宁（R）（多格列艾汀片）以葡萄糖传感器葡萄糖激酶为靶点，提升2型糖尿病患者的葡萄糖敏感性，改善患者血糖稳态失调。2022年9月30日，华堂宁（R）已获得中国国家药品监督管理局（NMPA）的上市批准，用于单独用药或者与二甲双胍联合用药，治疗成人2型糖尿病。对于肾功能不全患者，无需调整剂量，是一款可用于肾功能损伤的2型糖尿病患者的口服降糖药物。详情垂询华领医药网址：www.huamedicine.com投资者电邮：ir@huamedicine.com媒体电邮：pr@huamedicine.com Copyright 2024 亚太商讯 via SeaPRwire.com.

- 天然气总销量达171.3亿立方米；- 累计接驳居民、工业和商业用户分别达到4,795.6万户、2.6万户及38.5万户；- 天然气顺价加快落地 销气毛差同比上涨0.02元/m³至0.59元/m³；- 增值服务经营性利润同比增长15.4%至10.0亿港元；- 财务状况稳健，财务资源丰富，自由现金流达22.2亿港元，备用银行授信及获批准的人民币债券总额约1,049.1亿等值港元；- 中期派息每股15.0港仙。财务摘要 截至9月30日止六个月 20242023变化千港元千港元%收入35,105,20236,049,154(2.6)    天然气销售19,641,83621,718,489(9.6)    燃气接驳2,027,0382,308,096(12.2)    工程设计、建设及施工  1,308,4871,056,41223.9    液化石油气（「LPG」）销售9,557,9768,421,66313.5    增值服务                 2,012,9951,804,48611.6    其他业务556,870740,008(24.7)毛利5,855,6955,723,5732.3期间溢利2,263,9152,107,2037.4每股盈利（港仙）32.734.0(3.8)每股中期股息（港仙）15.015.0-  20249月30日20243月31日 变化千港元千港元%总资产153,473,528148,697,7243.2权益总额64,165,44260,747,3535.6银行结余及现金9,421,5978,280,33513.8香港, 2024年11月30日 - (亚太商讯 via SeaPRwire.com) - 国内具有领先地位的城市燃气营运商中国燃气控股有限公司（「中国燃气」或「集团」；股票编号：384）宣布其截至2024年9月30日止（「报告期」）之上半财年业绩。报告期内，为适时应对复杂多变的国际政治和经济形势，中国政府于九月开始推出稳定经济的措施。在一揽子有利政策的推动下，内地宏观经济有望持续回升向好，同时亦为提振天然气消费需求创造有利条件，城市燃气企业的盈利能力有望迎来修复，进入一个崭新发展期。此外，天然气上下游价格联动机制在全国范围内逐步落地，更多地区实现居民终端销售价格调整，销气毛差逐渐修复，进一步支撑天然气行业的健康及可持续发展。集团秉承"促回款、扩毛差、降费用、强组织、提品质、谋发展"的经营理念，积极探索创新业务的增长新路径，实现以燃气业务、增值服务、综合能源三大核心业务板块的协同发展。期内，集团录得营业额351.1亿港元，天然气售气总量达171.3亿立方米，自由现金流表现稳健，达22.2亿港元。董事会通过派付上半财年股息每股15.0港仙（2023/24年上半财年：15.0港仙），以回馈广大股东对集团的长期支持。加快天然气顺价落地，顺价比例及毛差进一步提高期内，集团抓住政策机遇，积极响应国家出台的天然气上下游价格联动机制及配气价格成本监审等政策，推动各地加快顺价，集团经营区域内新增20个市/县落实调价。截至2024年9月30日，集团累计完成居民气量顺价比例达62.2%，毛差修复至0.59元/m³，与去年相比取得稳步提升。期内，借助"老旧小区改造"和"瓶改管"等政策红利，新接驳904,232户居民用户、1,316户工业用户及24,906户商业用户。截至2024年9月30日，集团累计共为47,955,499户居民用户、25,792户工业用户及384,504户商业用户提供天然气服务，分别较去年同期增长约3.2%、10.7%和11.6%；集团城市燃气项目覆盖的可接驳户数达5,460万户。截至2024年9月30日，集团累计共于30个省、市、自治区取得662个拥有专营权的管道燃气项目，并拥有32个天然气长输管道、509座压缩/液化天然气加气站、一个煤层气开发项目及120个液化石油气分销项目。LPG业务保持高质量发展，持续优化纵向一体化协同作为中国规模最大、产业链最完整的综合性LPG运营服务商，集团业务覆盖全国22个省、市、自治区，目前运营5座液化石油气专用码头及6座大型石化产品仓储物流基地，码头年吞吐能力超过1,000万吨，总库容超过80万立方米。期内，集团实现销售液化石油气201.8万吨，销售收入总额达到95.6亿港元。集团持续优化纵向一体化协同，就上游而言，集团积极推进核心能力建设，提升国际贸易业务能力。期内，集团重构国际贸易团队和贸易风控体系，设立新加坡国际直采平台，在国际贸易业务方面取得实质性突破。于中游，集团推进仓储物流市场化运作，实现仓储物流资源整合，逐步提升仓储周转率，同时启动国内运贸平台建设，利用数字化赋能，扩大国内分销能力，从而提高国内分销与仓储物流效益。在下游端，集团推动创新业务模式与轻资产模式有效结合，通过迭代优化终端投资模式，丰富投资工具，助力终端业务高质量发展。增值服务营收利润双增长，未来发展空间巨大基于家庭场景，集团增值服务布局3大传统产品板块（厨房产品、安防产品、其它产品及服务）及4大新产品板块（电器、宜居、到家、优选）。目前增值服务业务遍及全国26个省、市、自治区，为用户提供产品及服务，不断增加用户覆盖，拓宽销售渠道。今年以来，中国消费市场保持稳定增长态势，政府出台多项政策鼓励家电以旧换新和家装消费品换新工程。集团把握政策机遇，于期内通过加快渠道建设、优化运营策略和强化终端赋能，实现增值服务收入同比增长11.6%至20.1亿港元；经营性利润同比增长15.4%至10.0亿港元。目前，集团通过不断深化传统渠道运营策略，优化产品结构，加快新业务拓展步伐，借助国家消费扶持政策，进一步扩大市场规模，未来发展空间巨大。积极探索综合能源业务商业模式，推进重点业务发展集团坚持以"绿色城市运营商"为战略定位，有效推进多业态融合、优化低能源成本综合方案以拓展市场、落地可长期发展的多赢商业模式。集团充分利用自身燃气项目的巨大市场和用户优势，通过外延式及内生性增长提升综合能源业务市场份额。期内，集团积极探索综合能源业务发展模式，锚定发展重点，投资及运营工商业用户侧储能、分布式光伏、锅炉节能、工商用户节能、建筑能效、充电桩、生物质能等业务。同时积极参与售电业务，并带动绿电绿证、碳排放因子库、虚拟电厂等业态快速扩充，为客户提供高效率的综合能源，满足客户对气、热、电、冷的不同需求。期内，储能及综合能效业务累计实现签约总装机容量318.4MWh，累计投建255.8MWh；售电业务交易量28.1亿度；绿证绿电业务完成销售8,196.4MWh。持续提升安全管理能力，积极推进老旧燃气管道等设施整改工作集团始终将安全管理视为核心任务，全面识别潜在风险，认真落实隐患整改，持续提升安全管理能力，为集团高质量发展营造安全稳定的环境。期内，集团通过开展专项治理工作，进一步规范基层员工操作，提升员工业务水平，并加强对燃气管道和相关设施关键信息的系统性收集，提升对管网资产的管理水平。同时，借助国家政策支持，集团积极推进老旧燃气管道和用户设施老化的更新改造与维护工作。此外，集团不断加强HSE体系审核认证及体系建设工作，建立健全集团双重预防机制管理模式，加强安全风险管控与隐患排查治理的闭环管理，并通过积极开展评级检查，有效提升了项目公司的安全管理水平。财务状况稳健截至2024年9月30日，集团总资产为1,534.7亿港元；银行结余及现金为94.2亿港元；期内集团通过执行严格的外币债务管理措施，及时合理地调整债务结构。集团一直积极与中国（包括香港）及外资银行建立长远合作关系，备用银行授信及获批准的人民币债券总额约1,049.1亿等值港元。行业发展及展望国际天然气价格在经历两年剧烈波动后，二零二四年以来重现平衡，供需端亦延续宽松态势。9月下旬开始，中国政府推出一系列稳经济、强信心的刺激政策，有助于经济复苏和房地产市场稳定，加上此前推出的"三大工程"、"超长期特别国债"、 "老旧管网更新"、"老旧小区改造"、"瓶改管"等利好燃气行业的政策，有利于稳固燃气行业根基。与此同时，各省市陆续发布和落实天然气上下游价格联动政策，有助于提升销气毛差，保障燃气企业的合理收益，促进天然气行业的健康长远发展。此外，全球低碳转型的浪潮不可阻挡，新能源和综合能源持续发展。集团将紧抓政策机遇，加快促进顺价落地，严控资本开支，推动数字化转型，进一步提升销气量及增值服务盈利水平，并全力推动综合能源项目发展，为国家经济发展提供"绿色"保障。集团主席兼总裁刘明辉先生表示："随着今年九月中国政府推出一系列旨在稳定市场的货币及财政政策以促进经济长期健康发展，相信更多具体、有力的稳经济政策将陆续出台，这些措施将提振资本市场信心，同时亦为中燃的业务发展提供良好的宏观环境。在宏观经济逐渐向好的大环境下，集团将发挥勇于创新变革的优良传统，不断优化业务模式，坚持高质量发展和可持续发展的策略，在不断做强集团燃气业务的基础上，继续深耕'客户导向'和'价值创造'，依托产业链延伸，拓展用户侧储能、生物质能等新业务，积极探索宜居、到家等增值服务新业态。同时，集团亦将把握机遇，紧跟政策、用好政策，缜密筹划，真正把国家政策红利转化为集团发展新动能，实现经营业绩与股东利益的双重增长。"有关中国燃气中国燃气控股有限公司（"中国燃气"，股票代号：384）是一家领先的燃气运营服务商，主要于中国从事投资、建设、经营城市燃气管道基础设施，向居民及工商业用户输送天然气和液化石油气，建设和经营车船用天然气加气站。同时，在庞大的燃气用户网络基础上，中国燃气打造了增值服务及综合能源并举的全业态发展结构。目前中国燃气在全国已拥有662个城镇的管道燃气专营权项目、32个天然气长输管道项目、509座压缩/液化天然气加气站，以及液化天然气等能源产品的进出口经营权，并拥有120个液化石油气分销项目。如欲获得更多中国燃气的资讯，请登入公司网址http://www.chinagasholdings.com.hk Copyright 2024 亚太商讯 via SeaPRwire.com.

香港, 2024年11月29日 - (亚太商讯 via SeaPRwire.com) - 香港董事学会昨晚在香港会议及展览中心举行的香港董事学会周年晚宴上公布2024年度董事嘉奖系列得奖者。奖项系列包括历来备受推祟的「杰出董事奬」及今年最新启动的「气候管治奖」。香港董事学会主席陶荣博士致辞并掀开晚宴序幕，亦邀请了大紫荆勋贤、香港特别行政区非官守议员郑慕智博士、中联办经济部徐卫刚部长、财经事务及库务局常任秘书长(财经事务)甄美薇女士, JP以及证券及期货事务监察委员会主席、会计及财务汇报局主席黄天佑博士，SBS ，JP​担任主礼嘉宾。今届报名参赛者十分踊跃，引发评审团热烈讨论。获奖者包括董事和董事会在内共19 名，充份演绎今年奖项主题「灵活领导 创意年代」真谛。获奖者不仅展现组织灵活性，更在严峻的营商环境和地缘政治紧张局势中发挥了领导者的远见、勇气和智慧。此外，董事们更承担起带领团队辨析气候变化所带来的危与机，以及对全球永续发展和人类福祉所带来的深远影响。以下为2024年度董事嘉奖系列得奖者:- 杰出董事简称「DYA」- 气候管治奖简称「CGA」排名以英文名称字母为序上市公司执行董事DYA陈伟明先生登辉控股有限公司CGA陈婉珊女士利记控股有限公司DYA傅帆先生中国太平洋保险（集团）股份有限公司CGA李伟梁先生恒安国际集团有限公司黄维义先生香港中华煤气有限公司DYA & CGA颜建国先生中国海外发展有限公司非执行董事DYA 钟瑞明博士中国中铁股份有限公司曾宪章博士TCL电子控股有限公司王一江教授TCL电子控股有限公司董事会DYA & CGA华润啤酒(控股)有限公司CGA香港中华煤气有限公司DYA & CGA中国平安保险（集团）股份有限公司CGA俄铝非上市公司执行董事DYA陈云美女士屈臣氏实业CGA郑文聪教授正昌科技(集团)有限公司郑世有博士工程师奥雅纳DYA柯家洋先生稳健医疗(香港)有限公司法定／非分配利润组织董事会DYA香港旅游发展局另获:董事会多元化卓越嘉许国际内部审计师协会（IIA）香港分会理事会另获:董事会多元化卓越嘉许前排的主禮嘉賓、官員以及香港董事學會的理事會成員一同和後排實至名歸的得獎者合照。香港董事学会董事嘉奖系列」「香港董事学会董事嘉奖系列」是香港董事学会（简称「学会」）举办的一个项目，包含两个奖项系列。第一个系列是「杰出董事奬」，自2001年举办，为首次在亚洲的创举。由于董事最终负责企业管治，以及带领公司实现繁荣和诚信，该奖项宗旨为彰显杰出董事会和董事，并推广优秀企业管治和董事专业行为。该奖项现已成为学会每年推动具影响力的一个社区项目，并得到100多个合作伙伴的支持。迄今，255位获奖者已因在企业管治和董事常规中展现卓越的标准而受到表彰。2024年启动的「气候管治奖」构成学会奖项的第二个系列。该奖项着眼于彰显及启发董事及董事会在气候管治的优秀成就，并提倡董事们采取有关气候的行动。首届获奖者共10位。现在是董事必须在董事会议程和管治职务中处理因气候变化带来风险和机遇的关键时刻。候选人可由公众提名，其资料透过严格的程序进行处理，经过与甄选顾问作高度尽职调查的会面，最后由拥有高标准和公正判断的独立评审团选出。奖项按公司类别，即上市公司、非上市公司和法定/非分配利润组织，亦按职务，即执行董事、非执行董事和董事会，进行颁发。香港董事学会（简称"HKIoD"，又以下简称「学会」）香港董事学会为香港代表董事共同努力的首要组织，其宗旨是促进企业永续发展职能，为所有公司、其拥有者、持份者、人类以至地球创造持久价值；为达成使命，学会致力于企业管治（「企业管治」又称「公司治理」）及董事专业行为上的倡导及厘定相关标准。学会于1997年由创会主席郑慕智博士带领下创始，多年来非常荣幸获得香港特别行政区行政长官担任学会赞助人。学会会员来自不同行业及公司类别，并包括执行董事、非执行董事、独立非执行董事。学会以多元文化及国际视野进行会务，举办活动包括董事培训课程、研讨会与论坛、董事立场喉舌、指引设定、公众教育、董事嘉奖系列、上市公司管治水平厘定等。作为「董事学会环球网络」（Global Network of Director Institutes 简称"GNDI")的成员组织，学会投入全球性联手推动优秀企业管治及董事专业行为。学会亦获委派代办「气候管治行动」(Climate Governance Initiative)之香港分部，该行动是与「世界经济论坛」（World Economic Forum）合作的环球网络，积极促进董事们处理气候变化带来的风险与机遇。详情请浏览：http://www.hkiod.com|http://www.gndi.org|https://climate-governance.org/新闻垂询：董事嘉奖系列奖查询：纵横公共关系顾问集团有限公司香港董事学会陈练 +852 2114 4396 / brenda.chan@sprg.com.hk苏佩君 +852 2889 9986/ odessa.so@hkiod.com Copyright 2024 亚太商讯 via SeaPRwire.com.

香港, 2024年11月29日 - (亚太商讯 via SeaPRwire.com) - 本港步入高龄化社会，为满足对优质养老之庞大需求，中银集团人寿保险有限公司（"中银人寿"）正式启动全球旅居养老金融布局，联动中国银行（香港）（"中银香港"）发挥"银行+保险"优势，率先推出"旅․心活"旅居体验计划（"旅․心活"）[1]，让港人以崭新的旅居方式，于"低物价指数、高生活品质"的宜居城市感受不同风土人情，深度体验以"六养合一"为理念的退休养老生活，尽情探索第二人生。"旅․心活"首阶段覆盖内地18大宜居城市，其中包括大湾区9个城市（除港澳外）；整体布局先聚焦大湾区及华南华东地区，再辐射全国，后至东南亚及全球。中银人寿同时提供一系列针对财富增值传承、退休年金及每月入息之保险产品，协助客户创造稳定现金流，建立养老生活财务支付基础，配合全新会员制旅居体验计划，加上中银香港跨境支付配套及专属消费优惠，让客户实践退休后动态慢活新方式。中银人寿率先推出市场首创"旅‧心活"旅居体验计划，让港人以崭新的旅居方式，尽情探索第二人生。（左至右）中银人寿市场及产品发展总监魏志炜先生、中银香港个人数字金融产品部总经理周国昌先生、中银人寿执行总裁邓子平先生、中银信用卡（国际）总经理何伟文先生、中银香港个人金融及财富管理部副总经理温晞文女士。中银人寿"旅․心活"会员尊享内地旅居基地礼遇和"六养合一"新体验"旅․心活"提供糅合健康养生与旅行居住的全新体验，拥有三大亮点，包括提供内地18个宜居城市作为旅居基地，让会员按照喜好及不同季节选择合适居住地；以"六养合一"理念，关注膳食、居住环境、医疗及社交等需求，缔造身心灵满足；专属旅居管家提供一对一谘询及礼宾服务，更会提供突发情况处理支援。中银人寿特选客户成功登记成为"旅․心活"会员后，即可尊享崭新旅居礼遇。1.强势布局：中银人寿依托中国银行和中银香港的强大资源，伙拍不同战略合作伙伴建立强大旅居网络，精心挑选内地18大旅居基地，涵盖杭州、成都、青岛、南京、福州、长沙、大理、三亚、黄山及珠海等及其他8个大湾区宜居城市，让"旅․心活"会员在不同季节选择最适合的旅居地，开启探索第二人生。2.六养合一：以"六养合一"为理念，包括食养（专业健康膳食方案）、住养（高端酒店式康养居住环境）、医养（养生设施及专业医疗康养服务）、动养（人性化生活设施配套及多元化康体活动课程）、旅养（一对一免费谘询及礼宾服务以满足休闲观光及深度旅游需求）、谊养（建立养老社区促进交际），全方位缔造身心灵满足。3.专属旅居管家 尊贵配套：专属旅居管家提供一对一谘询及礼宾服务，由前期的旅居行程设计、行程资源代订，入住期间的景点美食推荐，以及突发情况处理支援，专属旅居管家均能线上线下全方位支援。运用"银行＋保险"优势，结合非金融服务，携手打造优质退休生活中银人寿致力发挥"银行＋保险"的独特优势，为客户退休后的旅居新模式提供多面向全体验，包括伙拍中银香港推出多元化现金流产品，如"月悦出息终身享保险计划"、"中银人寿延期年金计划（终身）"等，实现理想退休生活。现凡投保"月悦出息终身享保险计划"[2]即可成为中银人寿特选客户，可登记成为"旅․心活"会员，享受品味生活的尊贵礼遇，更有机会获免费旅居套餐[3]，感受卓尔不凡的独特旅居体验。"旅‧心活"坐拥三大亮点，冀为客户带来"旅居养⽣"非凡新体验，实现理想退休生活。中银人寿未来将透过银行与保险的联动，让客户建立退休所需的财务保障，打造全方位的无忧退休方案。（左至右）艺人嘉宾黎彼得先生、中银信用卡助理总经理（信用卡业务）关文萱女士、中银香港个人金融及财富管理部副总经理温晞文女士、中银人寿市场及产品发展总监魏志炜先生、中银香港个人数字金融产品部助理总经理李健兴先生及艺人嘉宾孙慧雪女士。此外，为了协助港人无缝接轨内地消费模式，中银香港的中银银联双币卡及BoC Pay 电子钱包针对内地支付亦有一系列配套及专属优惠，推动客户于"旅․心活"18大旅居基地轻松享受无忧一站式跨境支付体验。同时，为协助港人实现不同的人生目标，"旅․心活"将进一步开放至中银香港"私人财富"客户，鼓励高端客户以崭新的旅居方式，打造惬意的优质退休生活，同时把财富代代相传。中银人寿执行总裁邓子平表示："中银人寿与中银香港将加强协同，充分运用'银行＋保险'优势，依托总行全球化及综合化资源，继续发挥领航者角色，与全球知名康养企业合作，共同建立'综合金融产品+多元养老服务'之养老金融服务方案，为客户缔造高品质的退休生活，满足市场庞大需求，积极推动银发经济发展，也为缓解香港高龄化社会问题贡献力量。"中银人寿市场及产品发展总监魏志炜表示："随著人口结构转变，人口老化成为全球各地及香港关注议题。中银人寿早前首推'旅․心活'试点计划，邀请100位特选客户体验旅居，获得高度正面回馈，展示旅居市场的巨大潜力。退休并不是终点，而是享受生活的起点－我们冀藉著推出全新会员计划，让更多港人认识'旅居退休'新模式，为他们的退休生活提供更多选择，呈献不一样的非金融体验。"中银人寿举办"2024旅居生活巡礼" 沉浸式体验旅居魅力为全面推广旅居概念，中银人寿举办"2024旅居生活巡礼"，透过沉浸式体验及精选特色活动，让参与者深入感受旅居城市的魅力及"六养合一"文化。中银人寿亦宣布冠名赞助HOY TV黄金时段节目 - 《中银人寿"旅․心活"旅居体验计划特约：退休旅居新模式》，希望协助港人轻松具体化退休后的理想旅居生活，并提早规划相对应的财务蓝图，发掘精彩第二人生。[1]更多中银人寿"旅․心活"旅居体验计划详情，请参阅：https://www.boclife.com.hk/tc/retirecation/home.html[2]更多"月悦出息终身享保险计划"计划详情，请参阅中银人寿公司网页以浏览产品小册子：https://www.boclife.com.hk/tc/product/incomejoy-lifelong-insurance-plan.html：[3]成功投保中银人寿指定保险产品，且符合指定保费要求，有机会尊享免费旅居体验套餐一次及专属旅居管家服务。优惠受条款及细则约束，详情请参阅：https://www.boclife.com.hk/tc/promotion/incomejoy-lifelong-insurance-plan-retirecation-reward.html Copyright 2024 亚太商讯 via SeaPRwire.com.

HONG KONG, Nov 28, 2024 - (ACN Newswire via SeaPRwire.com) - China’s largest retail digitalization solution provider– Dmall Inc. (“Dmall” or the “Company”, Stock Code: 02586.HK), today announced the proposed listing of its shares on the Main Board of The Stock Exchange of Hong Kong Limited (“Hong Kong Stock Exchange”).Dmall plans to offer 25,774,000 Shares (subject to the over-allotment option), of which 23,196,600 Shares will be International Offer Shares (subject to reallocation and the over-allotment option), representing approximately 90% of the initial offer shares; the remaining 2,577,400 Shares will be Hong Kong Offer Shares (subject to reallocation), representing approximately 10% of the initial offer shares. The Offer Price is HK$30.21 per Share, plus brokerage of 1.0%, SFC transaction levy of 0.0027%, Hong Kong Stock Exchange trading fee of 0.00565% and Accounting and Financial Reporting Council transaction levy of 0.00015% (payable in full on application in Hong Kong dollars and subject to refund).Dmall will open for Hong Kong Public Offering in Hong Kong at 9 a.m., November 28, 2024 (Thursday), and close at 11:30 a.m., December 3, 2024 (Tuesday). Dealings in shares of Dmall on the Main Board of the Hong Kong Stock Exchange is expected to commence on December 6, 2024 (Friday). The shares will be traded in board lot of 100 shares each. The Company’s stock code will be 02586.HK.UBS Securities Hong Kong Limited, CMB International Capital Limited and China Merchants Securities (HK) Co., Limited are the Joint Sponsors. UBS AG Hong Kong Branch, CMB International Capital Limited, China Merchants Securities (HK) Co., Limited, CLSA Limited and China International Capital Corporation Hong Kong Securities Limited are the Joint Global Coordinators, Overall Coordinators, Joint Bookrunners and Joint Lead Managers.After deducting the underwriting commissions and other estimated offering expenses payable by the Company, with an Offer Price of HK$30.21 per Offer Share, the Company estimates that it will receive net proceeds of approximately HK$623.7 million from the Global Offering after deducting the underwriting commissions and fees, and other estimated expenses in connection with the Global Offering and assuming that the Over-allotment Option is not exercised. In line with Dmall’s strategies, the proceeds from the Global Offering are intended to be used for the following purposes and in the following amounts – approximately 42.1%, or HK$262.6 million, to develop new applications and new service modules; approximately 30.0%, or HK$187.1 million, for talent acquisition associated with the expansion of Dmall’s operations; approximately 10.0%, or HK$62.4 million, to selectively pursue strategic cooperation, investments and acquisitions that are complementary to its organic growth strategies, particularly those that can complement Dmall’s product offerings, strengthen its technology capabilities, and solidify its market position; approximately 7.9%, or HK$49.3 million, to expand its sales network and further strengthen its brand reputation; and approximately 10.0%, or HK$62.4 million, for working capital and general corporate purposes.Dmall was founded in 2015, which provides retail digitalization solutions to retailers in the local retail industry. According to Frost & Sullivan, Dmall is the largest retail cloud solution provider in China by GMV, with a market share of 13.3% in 2023. The expansion has allowed the Company to become the largest retail cloud solution provider in Asia by GMV in 2023, occupied a market share of 10.9%, according to Frost & Sullivan.As a leading retail digitalization solution provider in Asia, the broadest operational modules coverage enables Dmall to cover diverse customer base in the retail industry and thus obtain deep retail know-how, meet the needs of all major aspects of the retailer's operations. Dmall served 444 customers in the six months ended June 30, 2024, such as Pangdonglai, Luosen (China), Dennis and Maidelong Entities, as well as well-known brands such as Wellcome, Mannings, Guardian, Giant and 7-Eleven (Hong Kong), which operate under the DFI Retail Group, demonstrating a widely validated operating model. The dollar-based net retention ratio was 184% in 2021, 158% in 2022, 117% in 2023 and 123% in the twelve months ended June 30, 2024, remaining robust at above 100%, which underscores Dmall’s ability to further increase customer spending.Dmall has always attached importance to the value created for customers, “customer success” is the starting point of everything the Company does. Dmall has provided services to leading companies in different retail formats, and has successfully expanded its businesses markets outside of the Chinese mainland, comprising Hong Kong SAR, Cambodia, Singapore, Malaysia, Poland, Macau SAR, Indonesia, the Philippines and Brunei. In terms of income, the overseas income of the Company in 2023 has exceeded RMB100 million.Dmall achieved strong revenue growth as its revenue grew by 56.6% from RMB848.2 million in 2021 to RMB1,328.3 million in 2022, and further increased by 19.4% to RMB1,585.4 million in 2023. Dmall’s revenue increased by 22.9% from RMB764.0 million in the six months ended June 30, 2023 to RMB939.2 million in the six months ended June 30, 2024. Dmall has also improved its gross margin during the Track Record Period. Dmall’s gross margins were 20.4%, 38.0%, 35.0%, 36.3% and 38.3% in the years ended December 31, 2021, 2022, 2023 and the six months ended June 30, 2023 and 2024, respectively.Mr. Zhang Feng, co-founder, executive Director and president of Dmall said, “We empower retailers to thrive in the digital era and are committed to becoming the world's leading omnichannel retail digital solutions provider. We will uphold the values of "continuous innovation", always strive, constantly strengthen and uphold our own technical barriers and optimize products and services, maintain core competitiveness, continue to provide customers with high-value services, and help customers' business. We look forward to taking the listing as an opportunity to fully leverage our competitive advantages and utilize Hong Kong's unique financing platform to further enhance our strengths and continue to create greater value for our shareholders and investors.”Issued by Porda Havas International Finance Communications Group for and on behalf of Dmall Inc. For further information, please contact:Porda Havas International Finance Communications GroupMS.Fung Kelly(852) 3150 6763kelly.fung@h-advisors.globalMS.Wang Evie(86) 135 2006 8960evie.wang@h-advisors.global  Copyright 2024 ACN Newswire via SeaPRwire.com.

香港, 2024年11月28日 - (亚太商讯 via SeaPRwire.com) - 在政策利好与市场氛围转暖的共振之下，2024年港股IPO市场复苏势头强劲，今年前三季度，香港IPO募资规模重回全球前四。亚洲物流巨头顺丰控股（6936.HK）已于11月27日登陆港交所，成为港股市场最大的物流领域上市企业、2023年以来港股第二大「A to H」 IPO项目，同时也是物流行业第一单「A to H」 IPO项目。在昨日的上市仪式上，顺丰创始人王卫先生表示在港上市对顺丰意义重大，集团可依托香港平台更好发展国际市场。王卫先生称，顺丰已经经营31年，7年前于A股上市，7年间集团面对不少困难，但团队有能力接受任何挑战，有丰富经验接受很多不能预控的因素。王卫先生在致辞中特别引用了广为传唱的粤语经典名歌曲《狮子山下》歌词，展现了其对顺丰未来发展的坚定信念与积极向往。顺丰在其发展过程中，也逐渐形成了与香港精神高度契合的企业精神，即拼搏进取、追求卓越、创新奉献、回馈社会。稀缺龙头：亚洲物流行业先锋与领导者顺丰控股于1993年在广东顺德创立，经过31年持续深耕，综合实力稳步增强，位居《财富》世界500强企业之列，2024年获评《财富》最受赞赏的中国公司第二位，这也是顺丰连续8年上榜「《财富》最受赞赏的中国公司」。一流的服务品质，令顺丰品牌在全球物流领域广获认可，品牌声誉卓著。根据弗若斯特沙利文，按2023年收入计，公司是中国及亚洲最大的综合物流服务提供商，也是全球第四大综合物流服务提供商，仅次于联合包裹服务公司（UPS）、敦豪（DHL）和联邦快递（FedEx）。直营模式、综合物流能力和独立第三方，构成顺丰控股业务模式的三个关键属性。顺丰直接经营从最初一公里收件到最后一公里派送的整个端到端物流流程，且是中国唯一一家独立于主要电商平台的规模化综合物流服务提供商，既提供全方位国内及国际物流服务，也向跨国公司、大型企业、中小型企业及散单客户提供一站式解决方案，为当今亚洲物流行业中独一无二的领军企业。盈利释放：多重因素带动盈利强劲增长2021年至2023年，顺丰控股收入、归母净利润复合年增长率分别达11.7%、31.9%，年末现金及现金等价物、和交易性金融资产从人民币452亿元增至人民币473亿元。2024年首三季度，公司各项业务增长延续稳健，同时调优网络结构，加强精益化资源规划与成本管控，整体营收同比增加9.4%，归母净利润同比增加21.6%。从各业务线来看，顺丰控股核心业务速运分部盈利相对稳定，鄂州枢纽投产料将夯实国内国际航网并提升资产利用率，大件、同城等新业务均兑现盈利并持续扩张，供应链及国际业务有望凭借中国企业出海以及供应链升级打造第二增长曲线。鉴于公司收入体量大，近两年均在2,500亿人民币以上，且盈利能力不断增强，在多网融通及营运模式变革下，降本增效持续兑现，将带来较大业绩弹性，带动盈利强劲增长。股东回报：积极回馈股东顺丰控股持续加大分红和回购力度。自2017年上市以来，公司每年均会宣派年度股息，派息率由2017年至2022年的20%提升至2023年的35%。公司于2024年10月公告中期分红将派息率提升到40%，并执行一次性特别分红，合计分红超人民币67亿元。根据公司未来五年（2024年-2028年）股东回报规划，现金分红比例将在2023年度基础上稳步提高。另外，从2022年开始，截至2024年10月31日，顺丰控股累计回购股份折合总金额约为人民币近48亿元，注销股份7,929万股，注销比例1.62%。选择在港股市场流动性增强、IPO发行环境改善的第四季度上市，对顺丰控股而言，是一个相当有利的时机。在香港资本市场的助力下，公司未来将进一步推进国际化战略、打造国际化资本运作平台、提升国际品牌形象及综合竞争力。 Copyright 2024 亚太商讯 via SeaPRwire.com.

香港, 2024年11月28日 - (亚太商讯 via SeaPRwire.com) - 中国最大的零售数字化解决方案服务商-多点数智有限公司（"多点"或"公司"，股份代号：02586.HK），今日宣布将于香港联合交易所有限公司 （"香港联交所"） 主板上市计划。多点将发售25,774,000股股份（视乎超额配股权行使与否而定），其中23,196,600股股份（可予重新分配及视乎超额配股权行使与否而定）将作国际发售，合共占初步发售股份总数的90%；馀下2,577,400股股份（(可予重新分配）将于香港作公开发售，合共占初步发售股份总数的10%，每股发售价为30.21港元，另加1.0%经纪佣金、0.0027%证监会交易征费、0.00565%香港联交所交易费及0.00015%会计及财务汇报局交易征费（须于申请时以港元缴足，且多缴股款可予退还）。多点将于2024年11月28日（星期四）上午9时开始于香港公开发售，并于2024年12月3日（星期二）上午11时30分截止。多点的股票预计将于2024年12月6日（星期五）于香港联交所主板开始进行买卖，股份将按每手买卖单位100股股份买卖，股票代号为02586.HK。UBS Securities Hong Kong Limited、招银国际融资有限公司、及招商证券（香港）有限公司为本次发行之联席保荐人。UBS AG Hong Kong Branch、招银国际融资有限公司、招商证券（香港）有限公司、中信里昂证券有限公司、中国国际金融香港证券有限公司为整体协调人、联席全球协调人、联席账簿管理人及联席牵头经办人。经扣除包销费用及其他与全球发售有关的估计开支后，按每股发售股份30.21港元计算，并假设超额配股权未获行使，公司估计将自全球发售收取所得款项净额约人民623.7百万港元。根据公司策略，其中约42.1%，或262.6百万港元将分配于开发新应用程式及新服务模块；约30.0%，或187.1百万港元将分配于与公司的业务扩张相关的人才招聘；约10.0%，或62.4百万港元将分配于选择性地寻求与多点的自然增长战略互补的战略合作、投资及收购，尤其是能够补公司的产品组合、增强公司的技术能力及巩固公司市场地位的战略合作、投资及收购；约7.9%，或49.3百万港元将分配于扩大公司的销售网络并进一步加强公司的品牌声誉；约10.0%，或62.4百万港元将用于营运资金及一般企业用途。多点成立于2015年，为本地零售业的零售商提供零售数字化解决方案。根据弗若斯特沙利文的资料，按商品交易总额计算，多点是2023年中国最大的零售云解决方案服务商，拥有13.3%的市场份额；按商品交易总额计算，多点成为2023年亚洲最大的零售云解决方案服务商，拥有10.9%的市场份额。作为亚洲领先的零售数字化解决方案服务商，多点覆盖了广泛的运营模组，触达了零售行业内多样化的客户群，从而获得深入的零售专业知识，满足零售商所有关键运营环节的需求。截至2024年6月30日，多点已为444名客户提供服务，包括胖东来‌、罗森（中国）、丹尼斯百货及麦德龙实体、以及DFI Retail Group经营的惠康、万宁、Guardian、Giant及7-11等知名品牌，运营模式受到广泛验证。于2021年、2022年、2023年及截至2024年6月30日止十二个月，净收益留存率分别为184%、158%、117%及123%，维持于100%以上的强劲水平，这凸显了其进一步增加客户消费的能力。多点自始至终重视为用户创造的价值，"客户成功"是多点一切工作的出发点。多点已经为零售行业各业态中的龙头企业提供服务，还成功将业务扩展至境外其他国家和地区，包括香港特别行政区、柬埔寨、新加坡、马来西亚、波兰、澳门特别行政区、印尼、菲律宾及汶莱。按收入计，2023年多点境外收入已突破亿元大关。于往绩记录期间，多点实现了强劲的收益增长，收益由2021年的人民币848.2百万元增加56.6%至2022年的人民币1,328.3百万元，并进一步增加19.4%至2023年的人民币1,585.4百万元。收益由截至2023年6月30日止六个月的人民币764.0百万元增加22.9%至截至2024年6月30日止六个月的人民币939.2百万元。于往绩记录期间，多点的毛利率亦有所改善。截至2021年、2022年、2023年12月31日止年度以及截至2023年及2024年6月30日止六个月，毛利率分别为20.4%、38.0%、35.0%、36.3%及38.3%。多点数智有限公司联合创始人、执行董事兼总裁张峰先生表示："我们助力零售赢在数字时代，致力于成为全球领先的全渠道零售数字化解决方案供应商。我们将秉持"持续创新"的价值观，始终奋斗，不断垒实自身技术壁垒并优化产品服务，保持核心竞争力，持续为客户提供高价值服务，助力客户业务。我们期待以上市为契机，充分发挥自身的竞争优势，利用香港特有的融资平台，进一步提升实力，为股东和投资者持续创造更大价值。"此新闻稿由博达浩华国际财经传讯集团代表多点数智有限公司发布。如有垂询，请联络︰博达浩华国际财经传讯集团冯嘉莉女士 (852)3150 6763 kelly.fung@h-advisors.global王佩女士 (86)135 2006 8960 evie.wang@h-advisors.global Copyright 2024 亚太商讯 via SeaPRwire.com.

香港, 2024年11月28日 - (亚太商讯 via SeaPRwire.com) - 11月27日，亚洲最大的综合物流服务提供商 - 顺丰控股（6936.HK）正式在港交所挂牌上市，成为又一家「A+H」企业。是次IPO，顺丰控股最终发售价为每股H股34.30港元，为招股发售价范围的中位数，募资总额为58.31亿港元。香港公开发售部分认购倍数达79.07倍，国际配售获10.10倍认购，上市港股总市值为1710.26亿港元（超额配售前）。随着利润持续兑现，港股上市后公司有望享受龙头估值溢价。坐拥多重优势，凸显行业龙头地位顺丰控股长期扎根物流行业，以直营、综合、独立为核心商业模式，通过不断创新与行业深耕，创造了可持续的竞争优势，成为亚洲规模最大的物流企业，且在全球四大综合物流服务提供商之中，也是收入增长最快、盈利能力增长最快的公司。根据弗若斯特沙利文报告（下同），按2023年收入计，顺丰控股是中国及亚洲最大的综合物流服务提供商，也是全球第四大综合物流服务提供商，仅次于联合包裹服务公司（UPS）、敦豪（DHL）和联邦快递（FedEx）。同时，顺丰控股还是时效快递领域当之无愧的领跑者，按2023年收入计，在中国的市场份额为63.9%。公司在包括快递、零担快运、冷运物流、第三方同城即时配送和民营独立第三方供应链解决方案等绝大多数物流细分领域均处于中国市场领导者地位。此外，亦是亚洲最大的快递、零担快运和同城即时配送物流提供商。公司的国际业务也在亚洲综合物流服务提供商中排名第一。物流网络遍布全球，稳居《财富》世界500强企业在亚洲物流服务提供商中，顺丰控股拥有最广泛的全球物流网络，持续助力其将商业模式成功复制到中国以外的亚洲其他市场乃至世界各地，建立全球影响力。公司位居《财富》世界500强企业之列，2024年获评《财富》最受赞赏的中国公司第二位，并连续8年上榜「《财富》最受赞赏的中国公司」。截至2024年6月30日，顺丰控股是中国最大的航空货运承运商，运营由99架全货机组成的亚洲最大的货机机队，在亚洲物流服务提供商中覆盖最多的国内和国际航线。截至同日，公司在全球范围内运营超过86,000辆干线及支线运输货车并拥有超过100,000辆收派配送车辆，这是亚洲最大的车队，覆盖亚洲最广泛的陆运网络。亦运营亚洲最广泛的服务网点网络和最大的收派员团队。货运枢纽方面，顺丰控股旗下鄂州货运枢纽是亚洲第一、全球第四座以货运为主的物流枢纽，具有战略价值和稀缺性。铁运方面，截至2023年12月31日，公司在亚洲物流服务提供商中运营的高铁线路以及国际线路数量最多，实现了亚洲最广泛的铁路覆盖。海运方面，按2023年TEU计，是亚洲第三大海运货运代理。庞大的业务规模与全球覆盖的物流网络，成就了顺丰控股稳固的行业领导地位。以「A+H」布局为支点，未来，公司将进一步在国际化征程中开疆扩土，打造新增长点。 Copyright 2024 亚太商讯 via SeaPRwire.com.

SAN FRANCISCO, CA & MUMBAI, Nov 28, 2024 - (ACN Newswire via SeaPRwire.com) - Niyo, India’s leading fintech startup, teamed up with CleverTap, the all-in-one engagement platform, to improve customer experiences through personalized engagement and real-time interactions. Since its founding in 2015, Niyo has been revolutionizing financial services in India, particularly with its international travel cards and app-based financial services, catering to the evolving needs of its users.In its almost decade-long journey, Niyo recognized the challenges that modern Indian travellers face at every touchpoint while venturing abroad. It sought a feature-rich user engagement platform that would effectively deliver the right solutions to its customers and found the ideal partner in CleverTap. By leveraging CleverTap’s advanced automation tools, Niyo enhanced its onboarding processes, while ensuring compliance with regulations, and streamlining customer experiences. This collaboration empowered Niyo to reduce drop-offs during the customer journey, automate personalized messages, and re-engage dormant users.By deploying CleverTap’s integrated platform, Niyo achieved:・2x increase in click through rates, leveraging Clever.AI for emotionally intelligent content.・40% optimized conversion rate through pinpoint targeting, ensuring personalized and relevant communication at every step.・12% re-engagement of dormant users through targeted campaigns, highlighting Niyo’s success in winning back inactive customers.Sushanth Ravikumar, SVP - Head of Marketing,  Niyo, said - “At Niyo, delivering a seamless and personalized experience for our customers is a top priority. CleverTap has been instrumental in elevating this experience. Its robust automation and communication tools have streamlined our onboarding process while maintaining compliance in the highly regulated sector. What started as a tool to streamline everyday operations has become a key force in helping us preserve customer trust, even during challenging times. Its ability to adapt to real-time shifts in customer engagement offers us a definitive edge in an ever-changing dynamic, solidifying our long-term confidence in the platform.”Sidharth Pisharoti, Chief Revenue Officer, CleverTap, said - “We are excited to collaborate with Niyo as they continue to innovate in the travel fintech space. Through our partnership, we’ve been able to enhance Niyo’s customer engagement by focusing on delivering personalized and timely experiences. This has not only streamlined their processes but also improved customer satisfaction, particularly in key areas like onboarding and transaction management. We look forward to supporting Niyo as they scale and evolve their offerings in this dynamic market.”About Niyo Niyo is India’s leading banking fintech that has revolutionized "travel banking" for Indians. The company was co-founded by banking veteran Vinay Bagri (currently, CEO) and technology veteran Virender Bisht (currently, CTO) in 2015. Niyo offers zero forex debit and credit cards, which provides the best banking experience and value for international travellers. This unique solution was invented by Niyo in 2015 and has helped over 2 million Indians by saving more up to 5% on their international transactions with Zero Forex offering.  In this last Series-C round in 2022, Niyo raised $130 million, which was led by global VC and PE firms, Accel, Lightrock, and Multiples. Its other investors include Prime Venture Partners, Horizons Ventures, Tencent, JS Capital, Social Capital, and Beams Fintech Fund. Niyo operates out of a corporate office in Bengaluru and has a sales presence in more than 20 states and union territories.Visit: GoNiyo.comAbout CleverTapCleverTap is the leading all-in-one customer engagement platform that helps brands unlock limitless customer lifetime value. CleverTap is trusted by over 2000 brands like Decathlon, Domino’s, Levis, Jio, Emirates NBD, Puma, Croma (A Tata Enterprise), Swiggy, SonyLIV, Axis Bank, AirAsia, TD Bank, Ooredoo, and Tesco, to help build personalized experiences for all their customers. The platform is powered by TesseractDB™ – the world’s first purpose-built database for customer engagement, offering speed and cost efficiency at scale.Backed by top-tier investors such as Accel, Peak XV Partners, Tiger Global, CDPQ and 360 One, the company is headquartered in San Francisco, with presence across Seattle, London, São Paulo, Bogota, Mexico, Amsterdam, Sofia, Dubai, Mumbai, Bangalore, Singapore, Vietnam, and Jakarta.For more information, visit CleverTap.com or follow us on:LinkedIn: https://www.linkedin.com/company/clevertap/  X: https://twitter.com/CleverTap  Forward-Looking StatementsSome of the statements in this press release may represent CleverTap's belief in connection with future events and may be forward-looking statements, or statements of future expectations based on currently available information. CleverTap cautions that such statements are naturally subject to risks and uncertainties that could result in the actual outcome being absolutely different from the results anticipated by the statements mentioned in the press release.Factors such as the development of general economic conditions affecting our business, future market conditions, our ability to maintain cost advantages, uncertainty with respect to earnings, corporate actions, client concentration, reduced demand, liability or damages in our service contracts, unusual catastrophic loss events, war, political instability, changes in government policies or laws, legal restrictions impacting our business, impact of pandemic, epidemic, any natural calamity and other factors that are naturally beyond our control, changes in the capital markets and other circumstances may cause the actual events or results to be materially different, from those anticipated by such statements. CleverTap does not make any representation or warranty, express or implied, as to the accuracy, completeness, or updated or revised status of such statements. Therefore, in no case whatsoever will CleverTap and its affiliate companies be liable to anyone for any decision made or action taken in conjunction.For more information:SONY SHETTYDirector, Communications and CSR, CleverTap+91 9820900036sony@clevertap.com  ASHMIT CHAUDHARYAssociate Consultant, Archetype+91 8850752121ashmit.chaudhary@archetype.co  Copyright 2024 ACN Newswire via SeaPRwire.com.